Login to Your Account

Bayer Has Solid Phase III

PAH Space Getting Hotter as Actelion Files Macitentan NDA

By Nuala Moran
Staff Writer

Wednesday, October 24, 2012
LONDON – There's a race to market for a new generation of pulmonary arterial hypertension (PAH) drugs with Actelion Ltd. announcing it has filed for FDA approval of Opsumit (macitentan) and Bayer Healthcare revealing positive Phase III data for riociguat and promising global filings in the first half of 2013.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription